Suzhou, China
Innovent Biologics
Chinese biopharmaceutical company listed in Hong Kong (HKEX: 01801) with products in cancer, autoimmune, cardiovascular and metabolic, and eye diseases. In GLP-1 medicines, it holds an exclusive licence from Eli Lilly to develop and commercialise mazdutide, a dual glucagon and GLP-1 receptor agonist, in China, where the drug has been approved for weight management and for type 2 diabetes.
Last verified 2026-09-29 · how we verify
Company website- Mazdutide approval for weight management (China)
- China's National Medical Products Administration (NMPA) approved mazdutide on 2025-06-27 for chronic weight management in Chinese adults with overweight or obesity, according to Innovent's announcement.[src]
- Mazdutide approval for type 2 diabetes (China)
- Innovent announced on 2025-09-19 that the NMPA had approved mazdutide for glycemic control in adults with type 2 diabetes.[src]
- Licence from Eli Lilly
- Innovent states it entered into an exclusive license agreement with Eli Lilly and Company for the development and potential commercialization of mazdutide in China.[src]
- 2025 revenue (company-reported)
- In its 2025 annual results Innovent reported total revenue of RMB 13.0 billion (+38.4%) and product revenue of RMB 11.9 billion (+44.6%). The announcement quoted here does not give a separate sales figure for mazdutide.[src]
Molecules
Key events
2025-06-27
China approves mazdutide for chronic weight management
Innovent announced on 27 June 2025 that China's NMPA approved mazdutide, a dual glucagon and GLP-1 receptor agonist, for chronic weight management in adults with overweight or obesity. The approval was supported by the GLORY-1 phase 3 trial.[src]
2025-05-25
GLORY-1: mazdutide produces about 14% weight loss at 48 weeks in Chinese adults
In the GLORY-1 phase 3 trial of 610 Chinese adults with obesity or overweight, mean body weight fell by up to 14.0% at week 48 with mazdutide, while the placebo group changed by +0.3%.[src]
Sources (5)
- 01Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight ManagementInnovent Biologics (via PR Newswire) · 2025-06-27 · accessed 2026-09-29
- 02Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 DiabetesInnovent Biologics (via PR Newswire) · 2025-09-19 · accessed 2026-09-29
- 03Innovent Announces 2025 Annual Results and Business UpdatesInnovent Biologics (via PR Newswire) · 2026-03-26 · accessed 2026-09-29
- 04Innovent Biologics corporate websiteInnovent Biologics · 2026 · accessed 2026-09-29
- 05Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)The New England Journal of Medicine · 2025-05-25 · accessed 2026-09-29